L

LivaNova

Cardiopulmonary and neuromodulation medical devices

Senior Quality Engineer

Full-Time
No salary listed
Senior
Bachelor's
Arvada, CO, USA
RemoteTravel is required approximately 20%.
Manufacturing Quality & TestQuality Engineering

About the job

Requirements
  • A minimum of 6 to 8 years of related work experience in medical device manufacturing, preferably Class II or III.
  • In-depth or broad engineering skills.
  • Proficiency with quality tools such as flowcharts, statistical data analysis, and mathematical reasoning.
  • Knowledge of regulatory requirements, including FDA and ISO requirements.
  • Ability to analyze and solve problems.
  • Ability to communicate across functional lines.
  • Ability to work in a clean room environment and tolerate chemical odors and the sight and smell of blood.
  • A bachelor's degree in a technical or scientific discipline such as Physics, Chemistry, Engineering, or Biology, or equivalent experience.
Responsibilities
  • Support Quality Engineering Management in managing design and manufacturing activities in compliance with Quality Management System requirements and applicable country regulations.
  • Cooperate in managing internal and external audits, interact with auditing organizations, and report on the Quality Management System to company managers.
  • Collect and critically analyze nonconforming product data and make disposition decisions while minimizing regulatory and patient risk.
  • Lead failure investigations and ensure systematic problem-solving methods are used and documented for nonconforming products and complaints.
  • Evaluate the risk posed by nonconformities in distributed products to determine whether stop shipment or field action should be proposed.
  • Maintain and update risk management reports documenting new issues or changes in severity or occurrence.
  • Provide input to the Corrective and Preventive Action process, analyze trend data, identify CAPA opportunities, and support or own CAPAs.
  • Identify and implement improvements within the Quality Management System.
  • Support Supplier Quality in managing nonconformities involving external manufacturers and service providers.
  • Establish product quality control plans commensurate with product risk.
  • Coordinate with Engineering to establish design verification and validation and process or software validation plans.
  • Review and provide input into process validation plans, protocols, and reports.
  • Perform preliminary reviews of change impact assessments to confirm that quality requirements are met.
  • Coordinate investigations into the causes of verification and validation failures using root cause analysis methods.
  • Identify quality improvement opportunities in production and lead improvement plans or projects.
  • Support complaint evaluations, complaint investigations, customer-related device-use processes, and customer quality and Medical Device Report/Vigilance metrics.
  • Develop and maintain relationships with internal and external stakeholders to assist customers and resolve complaints.
  • Interface with customers to understand details of trending issues and account-specific issues.
  • Monitor and maintain compliance with regulatory and company requirements, including FDA, ISO 13485, MDSAP, and medical device requirements.
  • Represent Quality in facility, product, or process change projects; communicate project status and remain accountable for project results.
  • Gather information from other departments to determine appropriate responses to issues and regulatory impacts.
  • Serve as a role model and develop the skills and competence of less experienced Quality Engineers, engineers, and technicians.
  • Conduct or assist with reviewing and evaluating personnel performance for direct reports or when otherwise requested.
Desired Qualifications
  • Experience in Class II or III medical device manufacturing.
  • ASQ Certified Quality Engineer or other ASQ certification.

About the company

LivaNova makes devices for heart surgery and neuromodulation therapies. Its neuromodulation products use an implanted generator with a lead that delivers electrical stimulation to the vagus nerve to help treat epilepsy and difficult-to-treat depression. In cardiac care, its devices support surgeons and clinicians during heart procedures, while the company has narrowed its portfolio to focus on these core areas. The goal is to improve outcomes for epilepsy and cardiac surgery and pursue growth in related areas like sleep apnea therapy.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Get referred to LivaNova

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 2Q 2026 revenue guidance rose to 8%–9%, driven by cardiopulmonary and epilepsy.
  • January 2026 Medicare reimbursement increases boosted VNS economics for epilepsy procedures.
  • Next-generation MRI-compatible aura6000 is targeted for 2027, expanding the OSA commercial runway.

What critics are saying

  • Third-party oxygenator and component shortages still constrain Essenz output and 2026 growth.
  • Heater-cooler litigation payments hit cash flow in 2026, with another $400 million expected.
  • Inspire and Nyxoah pressure OSA adoption, while CMS still delays treatment-resistant depression coverage.

What makes LivaNova unique

  • March 2026 aura6000 FDA approval gave LivaNova unique hypoglossal stimulation without CCC warning.
  • Essenz heart-lung machines and consumables anchor cardiopulmonary scale, with China launch in August 2025.
  • PolySync reprogramming lifted OSA response to 84.5%, strengthening LivaNova's differentiated platform economics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Employee Stock Purchase Plan
  • Flexible Work Hours
  • Paid Vacation

Company News

Yahoo Finance
Sep 11th, 2026
LivaNova director sells 17% of stake for $131,500

LivaNova director Francesco Bianchi sold 1,650 ordinary shares for $131,500 on 31 August 2026, according to an SEC Form 4 filing. The shares were sold at $79.72 each, whilst the stock closed at $80.16 the following day. The sale represented 17% of Bianchi's directly held shares prior to the transaction. Following the disposition, the director now holds 7,934 shares directly. LivaNova develops therapeutic medical devices across three segments: Cardiopulmonary products including oxygenators and heart-lung machines, Neuromodulation devices such as the VNS Therapy System, and Advanced Therapies solutions. The company has a market capitalisation of $4.3 billion and generated $1.5 billion in revenue over the trailing twelve months.

Business Wire
Jun 16th, 2026
LivaNova's PolySync programming achieves 84.5% response rate in obstructive sleep apnoea study

LivaNova has announced that its PolySync programming algorithm achieved an 84.5% cumulative response rate in patients with moderate to severe obstructive sleep apnea treated with proximal hypoglossal nerve stimulation. The findings were presented at SLEEP 2026 by lead author Alan Schwartz. The results build on LivaNova's OSPREY trial, which reported a 65% responder rate after 12 months. In the PolySync substudy, patients who initially did not respond underwent reprogramming using simultaneous-contact stimulation, converting most into responders and significantly improving outcomes. The approach was well tolerated with no serious adverse events. PolySync will be available with LivaNova's commercial product. The company is preparing its next-generation obstructive sleep apnea device for FDA submission in the second half of 2026, featuring MRI compatibility and rechargeable battery technology.

Business Wire
Jun 11th, 2026
Jette Nygaard-Andersen joins LivaNova board as medtech company reshuffles directors

LivaNova, a medical technology company, has appointed Jette Nygaard-Andersen to its Board of Directors following its Annual General Meeting on 10 June. Nygaard-Andersen currently chairs Coloplast A/S, a Danish medical device company, and previously served as CEO of Entain plc and in senior roles at Modern Times Group AB. The appointment coincides with Dr Sharon O'Kane stepping down after 10 years on the board. Brooke Story will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee, whilst Peter Wilver assumes leadership of the Compensation and Human Capital Management Committee. LivaNova develops medical solutions for neurological and cardiac conditions, employs approximately 3,300 people, and operates in over 100 countries.

Yahoo Finance
May 6th, 2026
LivaNova posts 10% organic growth in Q2 driven by cardiopulmonary momentum and neuromodulation gains

LivaNova reported 10% organic revenue growth in Q2 2025, driven by cardiopulmonary business momentum and solid neuromodulation performance across all regions. The company also delivered operating margin expansion and strong cash generation. The company announced key clinical milestones, including long-term results from the CORE-VNS study showing an 80% median seizure reduction at 36 months for focal onset seizures and 95% for focal to bilateral tonic-clonic seizures in drug-resistant epilepsy patients. LivaNova initiated the process with CMS to seek national Medicare coverage for VNS therapy in treatment-resistant depression patients, supported by five peer-reviewed publications from the RECOVER study. The company's obstructive sleep apnea programme remains in FDA review, with management expressing confidence in its proximal hypoglossal nerve stimulation technology.

Yahoo Finance
May 6th, 2026
LivaNova posts 13% organic revenue growth in Q3, driven by cardiopulmonary surge and epilepsy gains

LivaNova reported 13% organic revenue growth in Q3 2025, driven by strong performance in cardiopulmonary and epilepsy businesses. The cardiopulmonary segment generated $203 million in revenue, up 16% year-over-year, with heart-lung machine revenue growing over 20%. The company saw accelerated placements of its Essenz heart-lung machines, with most installations in developed markets. LivaNova launched Essenz in China, its second-largest market, in August, with positive early feedback. However, expansion remains constrained by third-party component supply despite progressing manufacturing capacity plans. LivaNova unveiled a refreshed brand identity and new strategic framework, which will be detailed at its investor day on 12 November. The company is focusing on near-term performance whilst investing in core businesses and developing programmes for obstructive sleep apnoea.